Division of Hematology and Medical Oncology and the Knight Cancer Institute, Oregon Health & Science University, CH-14R, 3303 SW Bond Ave, Portland, OR 97239, USA.
Cancer Causes Control. 2010 Aug;21(8):1297-303. doi: 10.1007/s10552-010-9557-y. Epub 2010 Apr 10.
Multiple studies have shown clear evidence of vitamin D's anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men.
We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men > or = 65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score.
In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50-1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results.
In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.
多项研究在实验室实验中均表明维生素 D 对前列腺癌细胞具有明显的抗肿瘤作用,但在人体中证据并不一致。我们试图在一组老年男性中研究维生素 D 与前列腺癌风险之间的关系。
我们进行了一项前瞻性病例-队列研究,该研究嵌套在多中心男性骨质疏松性骨折(MrOS)研究中。在没有前列腺癌病史且所有患有前列腺癌(n=297)的参与者中,从 1433 名年龄≥65 岁的随机选择的亚队列中测量了基线血清 25-羟维生素 D。使用 Cox 比例风险模型评估了总 25-羟维生素 D 四分位数与前列腺癌发病风险以及 Gleason 评分之间的关系。
与 25-羟维生素 D 的最低四分位数相比,25-羟维生素 D 的最高四分位数的风险比为 1.22(CI 0.50-1.72,p=0.25),四分位数之间无趋势(p=0.94)或与 Gleason 评分相关。调整协变量并未改变结果。
在这项针对老年男性的前瞻性队列研究中,我们未发现血清 25-羟维生素 D 水平与随后发生前列腺癌的风险之间存在关联。